Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
2.595
-0.075 (-2.81%)
Nov 21, 2024, 2:14 PM EST - Market open
Sutro Biopharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Sutro Biopharma stock have an average target of 12.14, with a low estimate of 8.00 and a high estimate of 17. The average target predicts an increase of 367.82% from the current stock price of 2.60.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for STRO stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +362.43% | Nov 18, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $11 | Buy | Reiterates | $11 | +323.89% | Oct 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +362.43% | Oct 11, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $17 | Buy | Reiterates | $17 | +555.11% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +362.43% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
67.38M
from 153.73M
Decreased by -56.17%
Revenue Next Year
64.95M
from 67.38M
Decreased by -3.61%
EPS This Year
-3.01
from -1.78
EPS Next Year
-3.05
from -3.01
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 95.4M | 105.3M | 158.8M | ||
| Avg | 67.4M | 65.0M | 74.5M | ||
| Low | 44.1M | n/a | 14.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -37.9% | 56.3% | 144.5% | ||
| Avg | -56.2% | -3.6% | 14.7% | ||
| Low | -71.3% | - | -77.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.08 | -1.76 | -1.40 | ||
| Avg | -3.01 | -3.05 | -2.79 | ||
| Low | -3.19 | -3.76 | -4.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.